← Back to Search

IDO1 Inhibitor

Pembrolizumab and Epacadostat for Thymoma

Phase 2
Waitlist Available
Led By Giuseppe Giaccone, MD PhD
Research Sponsored by Georgetown University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing a new treatment for cancer that has spread to the thymus. The treatment is a combination of two drugs, and it will be given to patients who have failed other treatments.

Eligible Conditions
  • Thymoma
  • Thymic Cancer
  • Thymic Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response Rate
Secondary outcome measures
Number of Participants With New-Onset Severe Adverse Events
Overall Survival
Progression-free Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pembrolizumab and EpacadostatExperimental Treatment2 Interventions
Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
Epacadostat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,886 Previous Clinical Trials
5,054,508 Total Patients Enrolled
3 Trials studying Thymoma
115 Patients Enrolled for Thymoma
Incyte CorporationIndustry Sponsor
364 Previous Clinical Trials
55,120 Total Patients Enrolled
Georgetown UniversityLead Sponsor
343 Previous Clinical Trials
136,457 Total Patients Enrolled
2 Trials studying Thymoma
26 Patients Enrolled for Thymoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
2015. "Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02364076.
All > Thymic Carcinoma
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top